RI-MUHC ANNUAL REPORT 2022
YEAR IN REVIEW
CANCER RESEARCH PROGRAM (CRP)
A new gene at the origin of some cases of ovarian cancer
For the first time, a research team led by Dr. Patricia Tonin linked mutations in the FANCI gene to the risk of developing ovarian cancer. Their findings show that a mutation in this gene is more common in ovarian cancer patients with a family history of ovarian cancer than in cancer-free people, suggesting that it may influence the risk of developing that cancer. This work lays the foundation for further studies to inform medical genetic screening practices for managing risk and ovarian cancer. (Genome Medicine)
Innovative device developed for gastroenterostomy bypass
Dr. Yen-I Chen leads the M-EPASS pilot study investigating a new approach to gastric outlet obstruction, a frequent complication of pancreatic cancer. His research team developed an innovative procedure: an ultrasound-guided double balloon to perform gastroenterostomy bypass. Results of the pilot study published in February 2022 show that M-EPASS appears to facilitate the technique of endoscopic ultrasound-guided gastroenterostomy (EUS-GE), potentially enhancing its safety and clinical adoption. (Endoscopy)
Critical finding for cancer immune therapy
Led by Ian Watson, PhD, a study featured on the cover of Science Immunology seeks to improve the treatment of melanoma, a deadly form of skin cancer. With collaborators from across Canada and the U.S., the team’s innovative approach highlights the relevance of the position of immune cells within the melanoma to inform on a patient's response to immune therapy. This ground-breaking work uses imaging mass cytometry, a new technique that retains spatial information about cell distribution in cancerous tumours. The results could improve prediction of melanoma patients’ response to immune therapy and offer insights that will guide personalized therapeutic approaches.
Selected CRP Program news links
- FANCI: a new gene at the origin of some cases of ovarian cancer
- Where immune cells are located is critical for cancer immune therapy, a new study shows
- RI-MUHC leads study to identify a novel mechanism driving aggressive prostate cancer
- Immunotherapy showing significant advancements in lung cancer treatment
- RI-MUHC team receives Discovery of the Year Award from Québec Science magazine
- RI-MUHC research team leads new consortium to make healthcare data more accessible
- RI-MUHC study shows impact of combinatorial immunotherapy on an aggressive cancer
- Promising development in the fight with cancer using artificial intelligence
- RI-MUHC team identifies potential diagnostic biomarker for pancreatic cancer
- MORE CRP news
Prisca Bustamante, Thupten Tsering, Jacqueline Coblentz, Christina Mastromonaco, Mohamed Abdouh, Cristina Fonseca, Rita P. Proença, Nadya Blanchard, Claude Laure Dugé, Rafaella Atherino Schmidt Andujar, Emma Youhnovska, Miguel N. Burnier, Sonia A. Callejo, Julia V. Burnier. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma. Journal of Experimental Clinical Cancer Res. 2021 Jun 16; 40(1):196. doi: 10.1186/s13046-021-01984-w.
Gautier Marcq, Luis Souhami, Fabio Luis B. Cury, Afsar Salimi, Armen G. Aprikian, Simon M. Tanguay, Marie Vanhuyse, Raghu D. Rajan, Fadi Brimo, José João C. Mansure, Wassim Kassouf. Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics. 2021 Jul 1; 110(3):738-741. doi: 10.1016/j.ijrobp.2020.12.033.
Yogesh M. Bramhecha, Karl-Philippe Guérard, Étienne Audet-Walsh, Shaghayegh Rouzbeh, Ola Kassem, Erwan Pernet, Eleonora Scarlata, Lucie Hamel, Fadi Brimo, Maziar Divangahi, Armen G. Aprikian, Simone Chevalier, Vincent Giguère, Jacques Lapointe. Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients. Oncogene. 2022 May; 41(20):2798-2810. doi: 10.1038/s41388-022-02276-z.
Masakazu Hashimoto, John David Konda, Stephanie Perrino, Maria Celia Fernandez, Andrew M. Lowy, Pnina Brodt. Targeting the IGF-Axis Potentiates Immunotherapy for Pancreatic Ductal Adenocarcinoma Liver Metastases by Altering the Immunosuppressive Microenvironment. Mol Cancer Ther. 2021 Dec; 20(12):2469-2482. doi: 10.1158/1535-7163.MCT-20-0144.
Abdenour Nabid, Nathalie Carrier, Eric Vigneault, Thu Van Nguyen, PeterVavassis, Marc-André Brassard, Boris Bahoric, Robert Archambault, François Vincent, Redouane Bettahar, Derek Wilke, Luis Souhami. Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial. International Journal of Radiation Oncology Biology Physics. 2021 Nov 1; 111(3):732-740. doi: 10.1016/j.ijrobp.2021.04.013.
Jun Tian, Vivian Wei Wang, Ni Wang, Baharak Khadang, Julien Boudreault, Khldoun Bakdounes, Suhad Ali, Jean Jacques Lebrun. Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition. Breast Cancer Res. 2021 Feb 15; 23(1):23. doi: 10.1186/s13058-021-01401-2.
Hossein Naseri, Kamran Kafi, Sonia R. Skamene, Marwan Tolba, Mame Daro Faye, Paul S. Ramia, Julia Khriguian, John Kildea. Development of a generalizable natural language processing pipeline to extract physician-reported pain from clinical reports: Generated using publicly-available datasets and tested on institutional clinical reports for cancer patients with bone metastases. J Biomed Inform. 2021 Aug; 120:103864. doi: 10.1016/j.jbi.2021.103864.
Shu Xing, Ives R. Levesque. A simulation study of cell size and volume fraction mapping for tissue with two underlying cell populations using diffusion-weighted MRI. Magnetic Resonance in Medicine. 2021 Aug; 86(2):1029-1044. doi: 10.1002/mrm.28694.
Yehonatan Nevo, Sarah Arjah, Amit Katz, Jose Luis Ramírez García Luna, Jonathan D. Spicer, Jonathan J. Cools-Lartigue, Carmen Leandra Mueller, Liane S. Feldman, Lorenzo Ferri. ERAS 2.0: Continued Refinement of an Established Enhanced Recovery Protocol for Esophagectomy. Annals of Surgical Oncology. 2021 Sep; 28(9):4850-4858. doi: 10.1245/s10434-021-09854-7.
Miran Rada, Migmar Tsamchoe, Audrey Kapelanski-Lamoureux, Nour Hassan, Jessica Bloom, Stephanie Petrillo, Diane H. Kim, Anthoula Lazaris,, Peter Metrakos. Cancer Cells Promote Phenotypic Alterations in Hepatocytes at the Edge of Cancer Cell Nests to Facilitate Vessel Co-Option Establishment in Colorectal Cancer Liver Metastases. Cancers (Basel). 2022 Mar 4; 14(5):1318. doi: 10.3390/cancers14051318.
Sylvie D. Lambert, Ekaterina Loban, Jane Li, Tracy Nghiem, Jamie Lynn Schaffler, Christine Maheu, Sylvie Dubois, Nathalie Folch, Elisa Gélinas-Phaneuf, Andréa Maria Laizner. Chronic Illness Management in Culturally and Linguistically Diverse Patients: Exploring the Needs, Access, and Understanding of Information. Qualitative Health Research. 2021 Nov;31(13):2426-2439. doi: 10.1177/10497323211040769.
Xiaoyang Liu, Farhad Maleki, Nikesh Muthukrishnan, Katie L. Ovens, Shaohui Huang, Almudena Pérez Lara, Griselda Teresa Romero-Sanchez, Sahir Rai Bhatnagar, Avishek Chatterjee, Marc Philippe Pusztaszeri, Alan Spatz, Gerald Batist, Seyedmehdi Payabvash, Stefan P Haider, Amit Mahajan, Caroline Reinhold, Behzad Forghani, Brian O'Sullivan, Eugene Yu, Reza Forghani. Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning Models. Cancers (Basel). 2021 Jul 24; 13(15):3723. doi: 10.3390/cancers13153723.